Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Aldesleukin

Aldesleukin

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Aldesleukin

43 trials tracked of Aldesleukin: 4 in phase 3 or 4.

43Trials tracked
4Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 39
  1. Phase 4 Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Completed
  2. Phase 3 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Completed
  3. Phase 3 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Completed
  4. Phase 3 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed
  5. Phase 2 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed
  6. Phase 2 Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma Completed
Show 37 more trials
  1. Phase 2 ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Completed
  2. Phase 2 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed
  3. Phase 2 Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma Completed
  4. Phase 2 Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma Completed
  5. Phase 2 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive Completed
  6. Phase 2 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed
  7. Phase 2 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Completed
  8. Phase 2 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed
  9. Phase 2 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma Completed
  10. Phase 2 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed
  11. Phase 2 Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant Completed
  12. Phase 2 DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC Completed
  13. Phase 2 CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma Completed
  14. Phase 2 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma Completed
  15. Phase 2 Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease Completed
  16. Phase 2 Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... Completed
  17. Phase 2 Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Completed
  18. Phase 2 Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes Completed
  19. Phase 2 Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma Completed
  20. Phase 2 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma Completed
  21. Phase 2 Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  22. Phase 2 Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  23. Phase 2 Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia Completed
  24. Phase 2 T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer Completed
  25. Phase 2 BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer Completed
  26. Phase 2 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma Completed
  27. Phase 2 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes Completed
  28. Phase 2 Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R Completed
  29. Phase 2 E7 TCR T Cells for Human Papillomavirus-Associated Cancers Completed
  30. Phase 2 Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia Completed
  31. Phase 2 Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... Completed
  32. Phase 2 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma Completed
  33. Phase 2 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Completed
  34. Phase 2 CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII Completed
  35. Phase 2 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma Completed
  36. Phase 2 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma Completed
  37. Phase 2 Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma Completed

Showing the 43 most-cited and recently-updated of 43 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.